Key result
Stage 2 CKM syndrome affects ~44% of US young adults, remaining stable over a decade.
Why the study?
What are the recent national prevalence estimates, temporal trends (2011–2020), and demographic disparities of cardiovascular-kidney-metabolic (CKM) syndrome stages among US young adults aged 18–39 years?
Cross-Sectional (n=7,331)
Yes
What are the recent national prevalence estimates, temporal trends (2011–2020), and demographic disparities of cardiovascular-kidney-metabolic (CKM) syndrome stages among US young adults aged 18–39 years?
Answers are grounded in this paper and cite their sources.
Nearly 80% of US young adults aged 18–39 years have CKM syndrome (over 45% at stage 2 or higher) with very low rates of medical therapy and notable sex and racial disparities, highlighting a critical window for early preventive intervention.
Background: Cardiovascular-kidney-metabolic (CKM) syndrome is a multistage, multisystem disorder defined by the American Heart Association (AHA). We examined recent trends in CKM stages among US young adults aged 18-39 years and assessed disparities by age, sex, and race/ethnicity. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) 2011-2020. Individuals were classified into CKM stages 0-4 based on metabolic, cardiovascular, and kidney risk factors. Results: Of the 7331 participants, 2202 (30.0%) were young adults. Among young adults, 48.2% were female and 56.9% non-Hispanic White. No significant temporal trends in CKM stage prevalence from 2011-2012 to 2017-2020 were observed among young adults and adults aged ≥40 years. In 2017-2020, among young adults, 20.4% (15.4% to 26.5%) had stage 0, 34.0% (28.5% to 40.0%) had stage 1, 44.4% (39.1% to 49.8%) had stage 2, and 1.2% had stage 3 or 4 CKM. Male and non-Hispanic Black young adults were more likely to have stage 2 or higher CKM compared to female and non-Hispanic White young adults. Among young adults with stage 2 CKM, 20.8% had stage 2 hypertension, 53.5% prediabetes, 3.4% diabetes, and 47.8% hypertriglyceridemia, and 8.9% high LDL-cholesterol ≥160 mg/dL; however, only 11.1% were on anti-hypertensive medications and 2.0% were on lipid-lowering medications. Conclusion: Over 45% of US young adults had stage 2 or higher CKM, with notable disparities by sex and race/ethnicity. Identification of young adults with CKM allows opportunities for early screening and tailored interventions to prevent progression to clinically significant cardiovascular or kidney disease.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) conducted a cross-sectional in Cardiovascular-kidney-metabolic (CKM) syndrome (n=7,331). Young adulthood (age 18-39 years) across NHANES survey cycles (2011-2012 to 2017-2020) vs. Adults aged ≥40 years and across demographic subgroups (sex, race/ethnicity) was evaluated on Age-standardized prevalence of CKM syndrome stage 2 among US young adults aged 18-39 years in 2017-2020 (95% CI 39.1%-49.8%, p=>0.05 for temporal trend). Among US young adults aged 18–39 years in 2017–2020, 44.4% had stage 2 and 1.2% had stage 3–4 CKM syndrome, with no significant temporal trends from 2011 to 2020.
Synapse has enriched 10 related papers. Consider them for comparative context: